Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Replimune Group Inc REPL

Healthcare Biotechnology
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a... see more

Recent & Breaking News (NDAQ:REPL)

Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting

GlobeNewswire June 6, 2023

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

GlobeNewswire June 5, 2023

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 3, 2023

Replimune to Present at the Jefferies Global Healthcare Conference

GlobeNewswire June 1, 2023

Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire May 25, 2023

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 18, 2023

Replimune to Participate in the Piper Sandler Spring Biopharma Symposium

GlobeNewswire May 9, 2023

Replimune to Present at Two Upcoming Investor Conferences

GlobeNewswire March 8, 2023

Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire February 9, 2023

Replimune to Present at the Virtual SVB Securities Global Biopharma Conference

GlobeNewswire February 7, 2023

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 4, 2023

Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer

GlobeNewswire January 4, 2023

Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2023

Replimune Announces Pricing of Public Offering

GlobeNewswire December 8, 2022

Replimune Announces Proposed Public Offering

GlobeNewswire December 7, 2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

GlobeNewswire December 7, 2022

Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma

GlobeNewswire December 7, 2022

Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference

GlobeNewswire November 23, 2022

Replimune to Host Virtual Investor Event on December 7, 2022

GlobeNewswire November 22, 2022

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 3, 2022